David D. Quiggle
Encore Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Cancer, Lipids, and Metabolism, Cancer, Hypoxia, and Metabolism, Estrogen and related hormone effects, Chemical Reaction Mechanisms
Most-Cited Works
- E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.(2000)
- → Treatment and survival study in the C57BL/6J-APCMin/+ (Min) mouse with R-flurbiprofen(2000)64 cited
- → Antiproliferative Effects of the Enantiomers of Flurbiprofen(1996)55 cited
- → Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic γ-Tocopherol Metabolite LLU-α(1997)39 cited
- → Endogenous Natriuretic Factors. 5. Synthesis and Biological Activity of a Natriuretic Metabolite of Diltiazem and Its Derivatives(1996)23 cited
- → Bioinversion of R‐flurbiprofen to S‐flurbiprofen at various dose levels in rat, mouse, and monkey(2004)23 cited
- → R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer(2000)9 cited
- The effects of R-flurbiprofen in reducing tumors in a multiple intestinal neoplasia mouse model(2001)
- → The effect of chronic versus acute administration on the anabolic effect of PGE2 on bone in the OVX rat(1996)
- → Increased expression of salivary gland EGF in the Min/ + mouse is reversed by R-flurbiprofen(1998)